Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Sandi Engler

Physician Assistant Summerville, SC Physician Assistant

NPI 1588643860 CMS profile 11090230

213 W 4Th North St, Summerville, SC 29483

Open in the dashboard

General payments

$6,696

364 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sandi Engler of Summerville, SC is reported in the CMS Open Payments database as having received $6,696 across 364 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,091 54
2024 General $1,359 66
2023 General $1,443 75
2022 General $1,582 93
2021 General $1,222 76

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sandi Engler
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Sandi Engler were reported at $1,091. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Sandi Engler Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,222 $132 $37–$438 $132
2022 $1,582 $155 $48–$522 $149
2023 $1,443 $167 $52–$557 $160
2024 $1,359 $178 $55–$600 $164
2025 $1,091 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $791 59 payments
  2. AstraZeneca Pharmaceuticals LP $639 34 payments
  3. Sanofi-Aventis U.S. LLC $419 20 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $339 14 payments
  5. GlaxoSmithKline, LLC. $333 20 payments
  6. Lilly USA, LLC $267 15 payments
  7. Supernus Pharmaceuticals, Inc. $256 7 payments
  8. Novo Nordisk Inc $252 16 payments
  9. Otsuka America Pharmaceutical, Inc. $239 13 payments
  10. ITI, Inc. $218 9 payments
  11. Other $2,944 157 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,696 364 payments
Products named General payments · program years 2021–2025
  1. FARXIGA $381 17 payments
  2. TOUJEO $342 14 payments
  3. VRAYLAR $327 25 payments
  4. UBRELVY $299 19 payments
  5. TRINTELLIX $285 11 payments
  6. GEMTESA $269 11 payments
  7. Qelbree $256 7 payments
  8. AIRSUPRA $256 11 payments
  9. REXULTI $239 13 payments
  10. TRELEGY ELLIPTA $238 14 payments
  11. Other $5,340 308 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 155 drugs

Part D claims

9,553

Median for Physician Assistant: 241

Drug cost

$863,584

Median for Physician Assistant: $4,110

Branded share of claims

22.9%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 105 $141,388
Jardiance Empagliflozin Brand 83 $87,443
Farxiga Dapagliflozin Propanediol Brand 80 $75,659
Eliquis Apixaban Brand 57 $75,179
Mounjaro Tirzepatide Brand 49 $62,838
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 44 $51,888
Januvia Sitagliptin Phosphate Brand 31 $38,128
Linzess Linaclotide Brand 29 $33,263
Entresto Sacubitril/Valsartan Brand 13 $25,931
Rybelsus Semaglutide Brand 13 $22,166

The 10 drugs with the highest cost, of 155 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 34 billing codes

Paid by Medicare

$77,515

Of which drugs: $2,962

Medicare patients

306

Average age 74

Services billed

2,102

225 women, 81 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 48%
Diabetes 32%
Chronic kidney disease 22%
Ischemic heart disease 19%
Depression 18%
COPD 17%
Osteoporosis 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Influenza vaccine, trivalent derived from cell cultures 90661 Office 38 38 $1,372
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 16 72 $41

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 34 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Qelbree
  • Supernus Pharmaceuticals, Inc. $256
$256 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $85
$85 80 —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $64
$64 — —
CAPLYTA
  • ITI, Inc. $60
$60 — —
GEMTESA
  • Sumitomo Pharma America, Inc. $57
$57 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 34 with Patron

Records

364 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record